| Literature DB >> 15247477 |
Marcel Leist1, Pietro Ghezzi, Giovanni Grasso, Roberto Bianchi, Pia Villa, Maddalena Fratelli, Costanza Savino, Marina Bianchi, Jacob Nielsen, Jens Gerwien, Pekka Kallunki, Anna Kirstine Larsen, Lone Helboe, Søren Christensen, Lars O Pedersen, Mette Nielsen, Lars Torup, Thomas Sager, Alessandra Sfacteria, Serhat Erbayraktar, Zubeyde Erbayraktar, Necati Gokmen, Osman Yilmaz, Carla Cerami-Hand, Qiao-Wen Xie, Thomas Coleman, Anthony Cerami, Michael Brines.
Abstract
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype-selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to the classical EPO receptor (EPOR) and did not show any hematopoietic activity in human cell signaling assays or upon chronic dosing in different animal species. Nevertheless, CEPO and various nonhematopoietic mutants were cytoprotective in vitro and conferred neuroprotection against stroke, spinal cord compression, diabetic neuropathy, and experimental autoimmune encephalomyelitis at a potency and efficacy comparable to EPO.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15247477 DOI： 10.1126/science.1098313
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728